TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology

STAMFORD, Conn.--(BUSINESS WIRE)--TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. Other investors include Rimonci Capital, and Sunmed Capital. The funding is allocated to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. “We're incre